APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-benzodiazepine Hypnotics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Non-benzodiazepine Hypnotics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025199 pages

Choose your research edition.

Industry ResearchNon-benzodiazepine Hypnotics Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-benzodiazepine Hypnotics Industry Growth and Trends Forecast to 2032128 pages · $3,450 USDMarket StructureGlobal Non-benzodiazepine Hypnotics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-benzodiazepine Hypnotics Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-benzodiazepine Hypnotics Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Non-benzodiazepine Hypnotics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Non-benzodiazepine Hypnotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-benzodiazepine Hypnotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-benzodiazepine Hypnotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Non-benzodiazepine Hypnotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Non-benzodiazepine Hypnotics include Abbott, Tianjin Tasly Saint Pharmaceuticals, Sun Pharmaceutical, Shanghai Pharmaceuticals, Qilu Pharmaceutical, Kanghong Pharmaceuticals, Changzhou Siyao Pharmaceutical, Wockhardt and Torrent Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Non-benzodiazepine Hypnotics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-benzodiazepine Hypnotics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-benzodiazepine Hypnotics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Non-benzodiazepine Hypnotics market size, projected growth trends, production technologies, key applications, and end-use industries.

Non-benzodiazepine Hypnotics Segment by Company

Abbott

Tianjin Tasly Saint Pharmaceuticals

Sun Pharmaceutical

Shanghai Pharmaceuticals

Qilu Pharmaceutical

Kanghong Pharmaceuticals

Changzhou Siyao Pharmaceutical

Wockhardt

Torrent Pharma

Teva Pharmaceuticals

Tapi Teva

Sanofi-aventis

Northstar Rx

Mylan Pharmaceuticals

Kanghong Pharmaceutical

Hikma Pharmaceuticals

Glenmark Life Sciences

Endo

Dr. Reddy’s Laboratories

Centaur Pharmaceuticals

Apotex

Admiron Life

Non-benzodiazepine Hypnotics Segment by Type

Zaleplon

Zopiclone

Zolpidem

Other

Non-benzodiazepine Hypnotics Segment by Application

Hospital

Clinic

Other

Non-benzodiazepine Hypnotics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-benzodiazepine Hypnotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-benzodiazepine Hypnotics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-benzodiazepine Hypnotics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Non-benzodiazepine Hypnotics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Non-benzodiazepine Hypnotics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Non-benzodiazepine Hypnotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Non-benzodiazepine Hypnotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Non-benzodiazepine Hypnotics Industry Trends Table 2. Non-benzodiazepine Hypnotics Industry Drivers Table 3. Non-benzodiazepine Hypnotics Industry Opportunities and Challenges Table 4. Non-benzodiazepine Hypnotics Industry Restraints Table 5. Global Non-benzodiazepine Hypnotics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Non-benzodiazepine Hypnotics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Non-benzodiazepine Hypnotics Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Non-benzodiazepine Hypnotics Sales Market Share by Manufacturers Table 9. Global Non-benzodiazepine Hypnotics Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Non-benzodiazepine Hypnotics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Non-benzodiazepine Hypnotics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Non-benzodiazepine Hypnotics Manufacturers, Product Type & Application Table 13. Global Non-benzodiazepine Hypnotics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Non-benzodiazepine Hypnotics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Zaleplon Table 17. Major Manufacturers of Zopiclone Table 18. Major Manufacturers of Zolpidem Table 19. Major Manufacturers of Other Table 20. Global Non-benzodiazepine Hypnotics Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Non-benzodiazepine Hypnotics Sales by Type (2021-2026) & (K Units) Table 22. Global Non-benzodiazepine Hypnotics Sales by Type (2027-2032) & (K Units) Table 23. Global Non-benzodiazepine Hypnotics Sales Market Share by Type (2021-2026) Table 24. Global Non-benzodiazepine Hypnotics Sales Market Share by Type (2027-2032) Table 25. Global Non-benzodiazepine Hypnotics Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Non-benzodiazepine Hypnotics Revenue by Type (2021-2026) & (K Units) Table 27. Global Non-benzodiazepine Hypnotics Revenue by Type (2027-2032) & (K Units) Table 28. Global Non-benzodiazepine Hypnotics Revenue Market Share by Type (2021-2026) Table 29. Global Non-benzodiazepine Hypnotics Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Other Table 33. Global Non-benzodiazepine Hypnotics Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Non-benzodiazepine Hypnotics Sales by Application (2021-2026) & (K Units) Table 35. Global Non-benzodiazepine Hypnotics Sales by Application (2027-2032) & (K Units) Table 36. Global Non-benzodiazepine Hypnotics Sales Market Share by Application (2021-2026) Table 37. Global Non-benzodiazepine Hypnotics Sales Market Share by Application (2027-2032) Table 38. Global Non-benzodiazepine Hypnotics Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Non-benzodiazepine Hypnotics Revenue by Application (2021-2026) & (K Units) Table 40. Global Non-benzodiazepine Hypnotics Revenue by Application (2027-2032) & (K Units) Table 41. Global Non-benzodiazepine Hypnotics Revenue Market Share by Application (2021-2026) Table 42. Global Non-benzodiazepine Hypnotics Revenue Market Share by Application (2027-2032) Table 43. Global Non-benzodiazepine Hypnotics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Non-benzodiazepine Hypnotics Sales by Region (2021-2026) & (K Units) Table 45. Global Non-benzodiazepine Hypnotics Sales Market Share by Region (2021-2026) Table 46. Global Non-benzodiazepine Hypnotics Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Non-benzodiazepine Hypnotics Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Non-benzodiazepine Hypnotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Non-benzodiazepine Hypnotics Sales by Country (2021-2026) & (K Units) Table 50. North America Non-benzodiazepine Hypnotics Sales by Country (2027-2032) & (K Units) Table 51. Europe Non-benzodiazepine Hypnotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Non-benzodiazepine Hypnotics Sales by Country (2021-2026) & (K Units) Table 53. Europe Non-benzodiazepine Hypnotics Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Non-benzodiazepine Hypnotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Non-benzodiazepine Hypnotics Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Non-benzodiazepine Hypnotics Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Non-benzodiazepine Hypnotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Non-benzodiazepine Hypnotics Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Non-benzodiazepine Hypnotics Sales by Country (2027-2032) & (K Units) Table 60. Global Non-benzodiazepine Hypnotics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Non-benzodiazepine Hypnotics Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Non-benzodiazepine Hypnotics Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Non-benzodiazepine Hypnotics Revenue Market Share by Region (2021-2026) Table 64. Global Non-benzodiazepine Hypnotics Revenue Market Share by Region (2027-2032) Table 65. Abbott Company Information Table 66. Abbott Business Overview Table 67. Abbott Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Abbott Non-benzodiazepine Hypnotics Product Portfolio Table 69. Abbott Recent Development Table 70. Tianjin Tasly Saint Pharmaceuticals Company Information Table 71. Tianjin Tasly Saint Pharmaceuticals Business Overview Table 72. Tianjin Tasly Saint Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Tianjin Tasly Saint Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 74. Tianjin Tasly Saint Pharmaceuticals Recent Development Table 75. Sun Pharmaceutical Company Information Table 76. Sun Pharmaceutical Business Overview Table 77. Sun Pharmaceutical Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sun Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio Table 79. Sun Pharmaceutical Recent Development Table 80. Shanghai Pharmaceuticals Company Information Table 81. Shanghai Pharmaceuticals Business Overview Table 82. Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 84. Shanghai Pharmaceuticals Recent Development Table 85. Qilu Pharmaceutical Company Information Table 86. Qilu Pharmaceutical Business Overview Table 87. Qilu Pharmaceutical Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Qilu Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio Table 89. Qilu Pharmaceutical Recent Development Table 90. Kanghong Pharmaceuticals Company Information Table 91. Kanghong Pharmaceuticals Business Overview Table 92. Kanghong Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Kanghong Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 94. Kanghong Pharmaceuticals Recent Development Table 95. Changzhou Siyao Pharmaceutical Company Information Table 96. Changzhou Siyao Pharmaceutical Business Overview Table 97. Changzhou Siyao Pharmaceutical Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Changzhou Siyao Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio Table 99. Changzhou Siyao Pharmaceutical Recent Development Table 100. Wockhardt Company Information Table 101. Wockhardt Business Overview Table 102. Wockhardt Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Wockhardt Non-benzodiazepine Hypnotics Product Portfolio Table 104. Wockhardt Recent Development Table 105. Torrent Pharma Company Information Table 106. Torrent Pharma Business Overview Table 107. Torrent Pharma Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Torrent Pharma Non-benzodiazepine Hypnotics Product Portfolio Table 109. Torrent Pharma Recent Development Table 110. Teva Pharmaceuticals Company Information Table 111. Teva Pharmaceuticals Business Overview Table 112. Teva Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Teva Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 114. Teva Pharmaceuticals Recent Development Table 115. Tapi Teva Company Information Table 116. Tapi Teva Business Overview Table 117. Tapi Teva Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Tapi Teva Non-benzodiazepine Hypnotics Product Portfolio Table 119. Tapi Teva Recent Development Table 120. Sanofi-aventis Company Information Table 121. Sanofi-aventis Business Overview Table 122. Sanofi-aventis Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Sanofi-aventis Non-benzodiazepine Hypnotics Product Portfolio Table 124. Sanofi-aventis Recent Development Table 125. Northstar Rx Company Information Table 126. Northstar Rx Business Overview Table 127. Northstar Rx Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Northstar Rx Non-benzodiazepine Hypnotics Product Portfolio Table 129. Northstar Rx Recent Development Table 130. Mylan Pharmaceuticals Company Information Table 131. Mylan Pharmaceuticals Business Overview Table 132. Mylan Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Mylan Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 134. Mylan Pharmaceuticals Recent Development Table 135. Kanghong Pharmaceutical Company Information Table 136. Kanghong Pharmaceutical Business Overview Table 137. Kanghong Pharmaceutical Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Kanghong Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio Table 139. Kanghong Pharmaceutical Recent Development Table 140. Hikma Pharmaceuticals Company Information Table 141. Hikma Pharmaceuticals Business Overview Table 142. Hikma Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Hikma Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 144. Hikma Pharmaceuticals Recent Development Table 145. Glenmark Life Sciences Company Information Table 146. Glenmark Life Sciences Business Overview Table 147. Glenmark Life Sciences Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Glenmark Life Sciences Non-benzodiazepine Hypnotics Product Portfolio Table 149. Glenmark Life Sciences Recent Development Table 150. Endo Company Information Table 151. Endo Business Overview Table 152. Endo Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Endo Non-benzodiazepine Hypnotics Product Portfolio Table 154. Endo Recent Development Table 155. Dr. Reddy’s Laboratories Company Information Table 156. Dr. Reddy’s Laboratories Business Overview Table 157. Dr. Reddy’s Laboratories Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Dr. Reddy’s Laboratories Non-benzodiazepine Hypnotics Product Portfolio Table 159. Dr. Reddy’s Laboratories Recent Development Table 160. Centaur Pharmaceuticals Company Information Table 161. Centaur Pharmaceuticals Business Overview Table 162. Centaur Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. Centaur Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 164. Centaur Pharmaceuticals Recent Development Table 165. Apotex Company Information Table 166. Apotex Business Overview Table 167. Apotex Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 168. Apotex Non-benzodiazepine Hypnotics Product Portfolio Table 169. Apotex Recent Development Table 170. Admiron Life Company Information Table 171. Admiron Life Business Overview Table 172. Admiron Life Non-benzodiazepine Hypnotics Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 173. Admiron Life Non-benzodiazepine Hypnotics Product Portfolio Table 174. Admiron Life Recent Development Table 175. Key Raw Materials Table 176. Raw Materials Key Suppliers Table 177. Non-benzodiazepine Hypnotics Distributors List Table 178. Non-benzodiazepine Hypnotics Customers List Table 179. Research Programs/Design for This Report Table 180. Authors List of This Report Table 181. Secondary Sources Table 182. Primary Sources List of Figures Figure 1. Non-benzodiazepine Hypnotics Product Image Figure 2. Global Non-benzodiazepine Hypnotics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-benzodiazepine Hypnotics Market Size (2021-2032) & (US$ Million) Figure 4. Global Non-benzodiazepine Hypnotics Sales (2021-2032) & (K Units) Figure 5. Global Non-benzodiazepine Hypnotics Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Non-benzodiazepine Hypnotics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Zaleplon Image Figure 9. Zopiclone Image Figure 10. Zolpidem Image Figure 11. Other Image Figure 12. Global Non-benzodiazepine Hypnotics Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Non-benzodiazepine Hypnotics Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Non-benzodiazepine Hypnotics Sales Market Share by Type (2021-2032) Figure 15. Global Non-benzodiazepine Hypnotics Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Non-benzodiazepine Hypnotics Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Non-benzodiazepine Hypnotics Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Other Image Figure 21. Global Non-benzodiazepine Hypnotics Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Non-benzodiazepine Hypnotics Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Non-benzodiazepine Hypnotics Sales Market Share by Application (2021-2032) Figure 24. Global Non-benzodiazepine Hypnotics Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Non-benzodiazepine Hypnotics Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Non-benzodiazepine Hypnotics Revenue Market Share by Application (2021-2032) Figure 27. North America Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Non-benzodiazepine Hypnotics Sales Market Share by Country (2021-2032) Figure 29. U.S. Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Non-benzodiazepine Hypnotics Sales Market Share by Country (2021-2032) Figure 34. Germany Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Non-benzodiazepine Hypnotics Sales Market Share by Country (2021-2032) Figure 41. China Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Non-benzodiazepine Hypnotics Sales Market Share by Country (2021-2032) Figure 49. Brazil Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Non-benzodiazepine Hypnotics Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Non-benzodiazepine Hypnotics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Non-benzodiazepine Hypnotics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Non-benzodiazepine Hypnotics Revenue (2021-2032) & (US$ Million) Figure 60. North America Non-benzodiazepine Hypnotics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Non-benzodiazepine Hypnotics Revenue (2021-2032) & (US$ Million) Figure 62. Europe Non-benzodiazepine Hypnotics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Non-benzodiazepine Hypnotics Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Non-benzodiazepine Hypnotics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Non-benzodiazepine Hypnotics Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Non-benzodiazepine Hypnotics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Non-benzodiazepine Hypnotics Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Non-benzodiazepine Hypnotics Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Zaleplon
  • Zopiclone
  • Zolpidem
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Abbott
  • Tianjin Tasly Saint Pharmaceuticals
  • Sun Pharmaceutical
  • Shanghai Pharmaceuticals
  • Qilu Pharmaceutical
  • Kanghong Pharmaceuticals
  • Changzhou Siyao Pharmaceutical
  • Wockhardt
  • Torrent Pharma
  • Teva Pharmaceuticals
  • Tapi Teva
  • Sanofi-aventis
  • Northstar Rx
  • Mylan Pharmaceuticals
  • Kanghong Pharmaceutical
  • Hikma Pharmaceuticals
  • Glenmark Life Sciences
  • Endo
  • Dr. Reddy’s Laboratories
  • Centaur Pharmaceuticals
  • Apotex
  • Admiron Life

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Non-benzodiazepine Hypnotics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Non-benzodiazepine Hypnotics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Non-benzodiazepine Hypnotics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Non-benzodiazepine Hypnotics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Non-benzodiazepine Hypnotics Market Dynamics
  1. 2.1 Non-benzodiazepine Hypnotics Industry Trends
  2. 2.2 Non-benzodiazepine Hypnotics Industry Drivers
  3. 2.3 Non-benzodiazepine Hypnotics Industry Opportunities and Challenges
  4. 2.4 Non-benzodiazepine Hypnotics Industry Restraints
3 Non-benzodiazepine Hypnotics Market by Manufacturers
  1. 3.1 Global Non-benzodiazepine Hypnotics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Non-benzodiazepine Hypnotics Sales by Manufacturers (2021-2026)
  3. 3.3 Global Non-benzodiazepine Hypnotics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Non-benzodiazepine Hypnotics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Non-benzodiazepine Hypnotics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Non-benzodiazepine Hypnotics Manufacturers, Product Type & Application
  7. 3.7 Global Non-benzodiazepine Hypnotics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Non-benzodiazepine Hypnotics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Non-benzodiazepine Hypnotics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Non-benzodiazepine Hypnotics Tier 1, Tier 2, and Tier 3
4 Non-benzodiazepine Hypnotics Market by Type
  1. 4.1 Non-benzodiazepine Hypnotics Type Introduction
  2. 4.1.1 Zaleplon
  3. 4.1.2 Zopiclone
  4. 4.1.3 Zolpidem
  5. 4.1.4 Other
  6. 4.2 Global Non-benzodiazepine Hypnotics Sales by Type
  7. 4.2.1 Global Non-benzodiazepine Hypnotics Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Non-benzodiazepine Hypnotics Sales by Type (2021-2032)
  9. 4.2.3 Global Non-benzodiazepine Hypnotics Sales Market Share by Type (2021-2032)
  10. 4.3 Global Non-benzodiazepine Hypnotics Revenue by Type
  11. 4.3.1 Global Non-benzodiazepine Hypnotics Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Non-benzodiazepine Hypnotics Revenue by Type (2021-2032)
  13. 4.3.3 Global Non-benzodiazepine Hypnotics Revenue Market Share by Type (2021-2032)
5 Non-benzodiazepine Hypnotics Market by Application
  1. 5.1 Non-benzodiazepine Hypnotics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Non-benzodiazepine Hypnotics Sales by Application
  6. 5.2.1 Global Non-benzodiazepine Hypnotics Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Non-benzodiazepine Hypnotics Sales by Application (2021-2032)
  8. 5.2.3 Global Non-benzodiazepine Hypnotics Sales Market Share by Application (2021-2032)
  9. 5.3 Global Non-benzodiazepine Hypnotics Revenue by Application
  10. 5.3.1 Global Non-benzodiazepine Hypnotics Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Non-benzodiazepine Hypnotics Revenue by Application (2021-2032)
  12. 5.3.3 Global Non-benzodiazepine Hypnotics Revenue Market Share by Application (2021-2032)
6 Global Non-benzodiazepine Hypnotics Sales by Region
  1. 6.1 Global Non-benzodiazepine Hypnotics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-benzodiazepine Hypnotics Sales by Region (2021-2032)
  3. 6.2.1 Global Non-benzodiazepine Hypnotics Sales by Region (2021-2026)
  4. 6.2.2 Global Non-benzodiazepine Hypnotics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Non-benzodiazepine Hypnotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Non-benzodiazepine Hypnotics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Non-benzodiazepine Hypnotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Non-benzodiazepine Hypnotics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Non-benzodiazepine Hypnotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Non-benzodiazepine Hypnotics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Non-benzodiazepine Hypnotics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Non-benzodiazepine Hypnotics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Non-benzodiazepine Hypnotics Revenue by Region
  1. 7.1 Global Non-benzodiazepine Hypnotics Revenue by Region
  2. 7.1.1 Global Non-benzodiazepine Hypnotics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Non-benzodiazepine Hypnotics Revenue by Region (2021-2026)
  4. 7.1.3 Global Non-benzodiazepine Hypnotics Revenue by Region (2027-2032)
  5. 7.1.4 Global Non-benzodiazepine Hypnotics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Non-benzodiazepine Hypnotics Revenue (2021-2032)
  8. 7.2.2 North America Non-benzodiazepine Hypnotics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Non-benzodiazepine Hypnotics Revenue (2021-2032)
  11. 7.3.2 Europe Non-benzodiazepine Hypnotics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Non-benzodiazepine Hypnotics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Non-benzodiazepine Hypnotics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Non-benzodiazepine Hypnotics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Non-benzodiazepine Hypnotics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Non-benzodiazepine Hypnotics Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Tianjin Tasly Saint Pharmaceuticals
  8. 8.2.1 Tianjin Tasly Saint Pharmaceuticals Company Information
  9. 8.2.2 Tianjin Tasly Saint Pharmaceuticals Business Overview
  10. 8.2.3 Tianjin Tasly Saint Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Tianjin Tasly Saint Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  12. 8.2.5 Tianjin Tasly Saint Pharmaceuticals Recent Developments
  13. 8.3 Sun Pharmaceutical
  14. 8.3.1 Sun Pharmaceutical Company Information
  15. 8.3.2 Sun Pharmaceutical Business Overview
  16. 8.3.3 Sun Pharmaceutical Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
  18. 8.3.5 Sun Pharmaceutical Recent Developments
  19. 8.4 Shanghai Pharmaceuticals
  20. 8.4.1 Shanghai Pharmaceuticals Company Information
  21. 8.4.2 Shanghai Pharmaceuticals Business Overview
  22. 8.4.3 Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  24. 8.4.5 Shanghai Pharmaceuticals Recent Developments
  25. 8.5 Qilu Pharmaceutical
  26. 8.5.1 Qilu Pharmaceutical Company Information
  27. 8.5.2 Qilu Pharmaceutical Business Overview
  28. 8.5.3 Qilu Pharmaceutical Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Qilu Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
  30. 8.5.5 Qilu Pharmaceutical Recent Developments
  31. 8.6 Kanghong Pharmaceuticals
  32. 8.6.1 Kanghong Pharmaceuticals Company Information
  33. 8.6.2 Kanghong Pharmaceuticals Business Overview
  34. 8.6.3 Kanghong Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kanghong Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  36. 8.6.5 Kanghong Pharmaceuticals Recent Developments
  37. 8.7 Changzhou Siyao Pharmaceutical
  38. 8.7.1 Changzhou Siyao Pharmaceutical Company Information
  39. 8.7.2 Changzhou Siyao Pharmaceutical Business Overview
  40. 8.7.3 Changzhou Siyao Pharmaceutical Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Changzhou Siyao Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
  42. 8.7.5 Changzhou Siyao Pharmaceutical Recent Developments
  43. 8.8 Wockhardt
  44. 8.8.1 Wockhardt Company Information
  45. 8.8.2 Wockhardt Business Overview
  46. 8.8.3 Wockhardt Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Wockhardt Non-benzodiazepine Hypnotics Product Portfolio
  48. 8.8.5 Wockhardt Recent Developments
  49. 8.9 Torrent Pharma
  50. 8.9.1 Torrent Pharma Company Information
  51. 8.9.2 Torrent Pharma Business Overview
  52. 8.9.3 Torrent Pharma Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Torrent Pharma Non-benzodiazepine Hypnotics Product Portfolio
  54. 8.9.5 Torrent Pharma Recent Developments
  55. 8.10 Teva Pharmaceuticals
  56. 8.10.1 Teva Pharmaceuticals Company Information
  57. 8.10.2 Teva Pharmaceuticals Business Overview
  58. 8.10.3 Teva Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  60. 8.10.5 Teva Pharmaceuticals Recent Developments
  61. 8.11 Tapi Teva
  62. 8.11.1 Tapi Teva Company Information
  63. 8.11.2 Tapi Teva Business Overview
  64. 8.11.3 Tapi Teva Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Tapi Teva Non-benzodiazepine Hypnotics Product Portfolio
  66. 8.11.5 Tapi Teva Recent Developments
  67. 8.12 Sanofi-aventis
  68. 8.12.1 Sanofi-aventis Company Information
  69. 8.12.2 Sanofi-aventis Business Overview
  70. 8.12.3 Sanofi-aventis Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi-aventis Non-benzodiazepine Hypnotics Product Portfolio
  72. 8.12.5 Sanofi-aventis Recent Developments
  73. 8.13 Northstar Rx
  74. 8.13.1 Northstar Rx Company Information
  75. 8.13.2 Northstar Rx Business Overview
  76. 8.13.3 Northstar Rx Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Northstar Rx Non-benzodiazepine Hypnotics Product Portfolio
  78. 8.13.5 Northstar Rx Recent Developments
  79. 8.14 Mylan Pharmaceuticals
  80. 8.14.1 Mylan Pharmaceuticals Company Information
  81. 8.14.2 Mylan Pharmaceuticals Business Overview
  82. 8.14.3 Mylan Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Mylan Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  84. 8.14.5 Mylan Pharmaceuticals Recent Developments
  85. 8.15 Kanghong Pharmaceutical
  86. 8.15.1 Kanghong Pharmaceutical Company Information
  87. 8.15.2 Kanghong Pharmaceutical Business Overview
  88. 8.15.3 Kanghong Pharmaceutical Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Kanghong Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
  90. 8.15.5 Kanghong Pharmaceutical Recent Developments
  91. 8.16 Hikma Pharmaceuticals
  92. 8.16.1 Hikma Pharmaceuticals Company Information
  93. 8.16.2 Hikma Pharmaceuticals Business Overview
  94. 8.16.3 Hikma Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Hikma Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  96. 8.16.5 Hikma Pharmaceuticals Recent Developments
  97. 8.17 Glenmark Life Sciences
  98. 8.17.1 Glenmark Life Sciences Company Information
  99. 8.17.2 Glenmark Life Sciences Business Overview
  100. 8.17.3 Glenmark Life Sciences Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Glenmark Life Sciences Non-benzodiazepine Hypnotics Product Portfolio
  102. 8.17.5 Glenmark Life Sciences Recent Developments
  103. 8.18 Endo
  104. 8.18.1 Endo Company Information
  105. 8.18.2 Endo Business Overview
  106. 8.18.3 Endo Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Endo Non-benzodiazepine Hypnotics Product Portfolio
  108. 8.18.5 Endo Recent Developments
  109. 8.19 Dr. Reddy’s Laboratories
  110. 8.19.1 Dr. Reddy’s Laboratories Company Information
  111. 8.19.2 Dr. Reddy’s Laboratories Business Overview
  112. 8.19.3 Dr. Reddy’s Laboratories Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Dr. Reddy’s Laboratories Non-benzodiazepine Hypnotics Product Portfolio
  114. 8.19.5 Dr. Reddy’s Laboratories Recent Developments
  115. 8.20 Centaur Pharmaceuticals
  116. 8.20.1 Centaur Pharmaceuticals Company Information
  117. 8.20.2 Centaur Pharmaceuticals Business Overview
  118. 8.20.3 Centaur Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Centaur Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  120. 8.20.5 Centaur Pharmaceuticals Recent Developments
  121. 8.21 Apotex
  122. 8.21.1 Apotex Company Information
  123. 8.21.2 Apotex Business Overview
  124. 8.21.3 Apotex Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Apotex Non-benzodiazepine Hypnotics Product Portfolio
  126. 8.21.5 Apotex Recent Developments
  127. 8.22 Admiron Life
  128. 8.22.1 Admiron Life Company Information
  129. 8.22.2 Admiron Life Business Overview
  130. 8.22.3 Admiron Life Non-benzodiazepine Hypnotics Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Admiron Life Non-benzodiazepine Hypnotics Product Portfolio
  132. 8.22.5 Admiron Life Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Non-benzodiazepine Hypnotics Value Chain Analysis
  2. 9.1.1 Non-benzodiazepine Hypnotics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Non-benzodiazepine Hypnotics Production Mode & Process
  6. 9.2 Non-benzodiazepine Hypnotics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Non-benzodiazepine Hypnotics Distributors
  9. 9.2.3 Non-benzodiazepine Hypnotics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst